Skandinaviska Enskilda Banken Ab (Publ) Atara Biotherapeutics, Inc. Transaction History

Skandinaviska Enskilda Banken Ab (Publ)

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 10, 2021	SELL	$12.89 - $16.58 $466,128 - $599,565	-36,162 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$14.0 - $20.72 $506,268 - $749,276	36,162 New	36,162 $519,000
Q4 2020 Feb 11, 2021	SELL	$12.67 - $26.23 $458,172 - $948,529	-36,162 Closed	0 $0
Q3 2020 Nov 12, 2020	BUY	$11.92 - $15.87 $431,051 - $573,890	36,162 New	36,162 $469,000
Q4 2019 Feb 14, 2020	SELL	$10.89 - $16.79 $393,804 - $607,159	-36,162 Closed	0 $0
Q3 2019 Nov 08, 2019	BUY	$12.03 - $19.94 $435,028 - $721,070	36,162 New	36,162 $511,000

2.89M

Ticker ATRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,362,304
Market Cap $1.59B
Description
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...

Get notified when there are updates to the investment portfolio of Skandinaviska Enskilda Banken Ab (Publ), based on Form 13F filings with the SEC.

Stay updated on Skandinaviska Enskilda Banken Ab (Publ) with notifications on news.